PROK

ProKidney is a clinical-stage biotech whose entire value rests on a single asset, rilparencel (REACT), an autologous cell therapy in the Phase 3 REGEN-006 (PROACT 1) trial for advanced CKD with type 2 diabetes. Management states plainly it has 'not generated any revenue from product sales' and does 'not expect to generate any revenue from the sale of products in the near future, if at all.' The $893K of FY2025 revenue — despite a headline +1075% YoY — is merely leasing income from two Winston-Salem buildings, not commercial traction, which is why the P/S of ~140x is economically meaningless. This is a story stock priced on a trial readout, not on financials.

The numbers underline how binary and fragile the position is. The company posted a $69.0M net loss and a $165M operating loss in FY2025, burned $120M of operating cash, and spent $114M on R&D — against just $109M of cash on hand. That is roughly one year of runway before another raise, and the 10-K itself warns expenses 'will increase substantially' as it advances confirmatory trials, builds cGMP manufacturing, and stands up commercial infrastructure. With only 61.5M shares and a $125M market cap, the near-certain equity financing to bridge to any approval is highly dilutive at a depressed $2.03 price. The accumulated deficit is $1.27B and losses before noncontrolling interest have run $135–163M annually for three years.